Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00444600 · ClinicalTrials.gov registry record · Phase 3
Laser-Ranibizumab-Triamcinolone for Diabetic Macular Edema
A Phase 3 study, sponsored by Jaeb Center for Health Research.
- Completed
- Registry status
- Phase 3
- Development phase
- 691
- Enrollment target
NCT00444600 is a Phase 3 study that has completed, run by Jaeb Center for Health Research. The registered enrollment target is 691 participants.
The verdict
NCT00444600, a Phase 3 study, has completed, sponsored by Jaeb Center for Health Research.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 691 participants
- Enrollment target
Study Summary
The purpose of the study is to find out which is a better treatment for diabetic macular edema (DME): laser alone, laser combined with an intravitreal injection of triamcinolone, laser combined with an intravitreal injection of ranibizumab, or intravitreal injection of ranibizumab alone. At the present time, it is not known whether intravitreal steroid or anti-vascular endothelial growth factor (anti-VEGF) injections, with or without laser treatment, are better than just laser by itself. It is possible that one or both of the types of injections, with or without laser treatment, will improve vision more often than will laser without injections. However, even if better vision outcomes are seen with injections, side effects may be more of a problem with the injections than with laser. Therefore, this study is conducted to find out whether the benefits of the injections will outweigh the risks.
Interventions
- DRUG Triamcinolone Acetonide + laser
- DRUG Ranibizumab + laser
- DRUG Sham injection + laser
- DRUG Ranibizumab + deferred laser
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 691 participants |
| Start Date | 2007-03 |
| Est. Completion | 2014-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00444600
The ClinicalTrials.gov registry entry for NCT00444600 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 691 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Jaeb Center for Health Research, which has 119 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Triamcinolone Acetonide + laser is the first listed.
NCT00444600 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00444600 about?
NCT00444600 is a clinical study titled "Laser-Ranibizumab-Triamcinolone for Diabetic Macular Edema". The purpose of the study is to find out which is a better treatment for diabetic macular edema (DME): laser alone, laser combined with an intravitreal injection of triamcinolone, laser combined with an intravitreal injection of ranibizumab, or intravitreal injection of ranibizumab alone. At the pres...
What is the current status of trial NCT00444600?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 691 participants. The study started on 2007-03. Estimated completion is 2014-02.
What interventions are being tested in trial NCT00444600?
The interventions under investigation include: Triamcinolone Acetonide + laser (DRUG), Ranibizumab + laser (DRUG), Sham injection + laser (DRUG), Ranibizumab + deferred laser (DRUG).
Who is sponsoring clinical trial NCT00444600?
This trial is sponsored by Jaeb Center for Health Research, which has 119 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.